On April 17, 2024, Exicure, Inc., a biotechnology company, received a delinquency notification from the Nasdaq Stock Market for not filing its annual report on Form 10-K for the year ended December 31, 2023. This failure to file has resulted in non-compliance with Nasdaq Listing Rule 5250(c)(1), which mandates timely submission of periodic financial reports to the SEC. The company had previously been granted an extension until May 20, 2024, to file its delinquent third quarter Form 10-Q and now must also file the overdue Form 10-K by the same date to regain compliance. Exicure's management is actively working to complete the Form 10-K and plans to submit it as soon as possible. The company, which has suspended its clinical and development activities, is currently exploring strategic alternatives to enhance stockholder value.

On April 17, 2024, Exicure, Inc., a biotechnology company, received a delinquency notification from the Nasdaq Stock Market for not filing its annual report on Form 10-K for the year ended December 31, 2023. This failure to file has resulted in non-compliance with Nasdaq Listing Rule 5250(c)(1), which mandates timely submission of periodic financial reports to the SEC. The company had previously been granted an extension until May 20, 2024, to file its delinquent third quarter Form 10-Q and now must also file the overdue Form 10-K by the same date to regain compliance. Exicure's management is actively working to complete the Form 10-K and plans to submit it as soon as possible. The company, which has suspended its clinical and development activities, is currently exploring strategic alternatives to enhance stockholder value.